The University of Chicago Header Logo

Connection

George Perry to Aged

Back to Details
This is a "connection" page, showing publications George Perry has written about Aged.
George Perry
Connection Strength
0.561
Aged
  1. Analysis of Alzheimer's Disease-Related Mortality Rates Among the Elderly Populations Across the United States: An Analysis of Demographic and Regional Disparities from 1999 to 2020. Curr Alzheimer Res. 2024; 21(6):384-394.
    View in: PubMed
    Score: 0.060
  2. Alzheimer's Disease: Not Just for the Aged? J Alzheimers Dis. 2023; 91(3):923-924.
    View in: PubMed
    Score: 0.056
  3. Lessons from antiamyloid-ß immunotherapies in Alzheimer's disease. Handb Clin Neurol. 2023; 193:267-292.
    View in: PubMed
    Score: 0.056
  4. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics. 2019 07; 16(3):666-674.
    View in: PubMed
    Score: 0.044
  5. Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radic Biol Med. 2012 Feb 01; 52(3):699-704.
    View in: PubMed
    Score: 0.026
  6. Where does the neighborhood go? Trust, social engagement, and health among older adults in Baltimore City. Health Place. 2016 09; 41:58-66.
    View in: PubMed
    Score: 0.018
  7. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol. 2005 Sep; 110(3):232-8.
    View in: PubMed
    Score: 0.017
  8. Identifying patients with mild cognitive impairment at high risk of transitioning to Alzheimer's disease using routinely collected data. J Alzheimers Dis. 2025 Nov; 108(1_suppl):S334-S343.
    View in: PubMed
    Score: 0.017
  9. Exacerbated mitochondrial dynamic abnormalities without evident tau pathology in rapidly progressive Alzheimer's disease. J Alzheimers Dis. 2024 Dec; 102(4):1074-1083.
    View in: PubMed
    Score: 0.016
  10. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024 Dec; 20(12):8661-8672.
    View in: PubMed
    Score: 0.016
  11. Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on a-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 11 01; 14(21):3913-3927.
    View in: PubMed
    Score: 0.015
  12. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol. 2003 Dec; 106(6):552-6.
    View in: PubMed
    Score: 0.015
  13. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol. 2003 May; 162(5):1623-7.
    View in: PubMed
    Score: 0.014
  14. Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. Neuroreport. 2002 Nov 15; 13(16):2035-9.
    View in: PubMed
    Score: 0.014
  15. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine. 2020 Jul; 57:102834.
    View in: PubMed
    Score: 0.012
  16. No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. J Alzheimers Dis. 2019; 67(4):1277-1289.
    View in: PubMed
    Score: 0.011
  17. Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study. J Alzheimers Dis. 2019; 71(2):631-645.
    View in: PubMed
    Score: 0.011
  18. Neuropathology in Consecutive Forensic Consultation Cases with a History of Remote Traumatic Brain Injury. J Alzheimers Dis. 2019; 72(3):683-691.
    View in: PubMed
    Score: 0.011
  19. Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies. Biochim Biophys Acta Mol Basis Dis. 2019 08 01; 1865(8):2048-2059.
    View in: PubMed
    Score: 0.010
  20. Differences in structure and function between human and murine tau. Biochim Biophys Acta Mol Basis Dis. 2019 08 01; 1865(8):2024-2030.
    View in: PubMed
    Score: 0.010
  21. Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data. J Alzheimers Dis. 2018; 63(4):1269-1277.
    View in: PubMed
    Score: 0.010
  22. Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology. J Alzheimers Dis. 2017; 55(2):749-762.
    View in: PubMed
    Score: 0.009
  23. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015; 44(2):549-60.
    View in: PubMed
    Score: 0.008
  24. Accumulation of intraneuronal amyloid-ß is common in normal brain. Curr Alzheimer Res. 2014 May; 11(4):317-24.
    View in: PubMed
    Score: 0.008
  25. Antimicrobial peptide ß-defensin-1 expression is upregulated in Alzheimer's brain. J Neuroinflammation. 2013 Oct 18; 10:127.
    View in: PubMed
    Score: 0.007
  26. A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. Lab Invest. 2011 Dec; 91(12):1777-86.
    View in: PubMed
    Score: 0.006
  27. The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol. 2011 Jul; 70(7):578-87.
    View in: PubMed
    Score: 0.006
  28. Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology. 2010 Dec; 30(6):574-9.
    View in: PubMed
    Score: 0.006
  29. CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease. J Neural Transm (Vienna). 2011 Jan; 118(1):23-6.
    View in: PubMed
    Score: 0.006
  30. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol. 2010 Aug; 68(2):162-72.
    View in: PubMed
    Score: 0.006
  31. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 2010; 15(4):161-8.
    View in: PubMed
    Score: 0.006
  32. Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging (Albany NY). 2009 Apr; 1(4):382-8.
    View in: PubMed
    Score: 0.005
  33. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem. 2008 Aug; 106(3):1350-6.
    View in: PubMed
    Score: 0.005
  34. Redox active iron accumulation in aceruloplasminemia. Neuropathology. 2008 Oct; 28(5):466-71.
    View in: PubMed
    Score: 0.005
  35. Increased expression of p130 in Alzheimer disease. Neurochem Res. 2007 Apr-May; 32(4-5):639-44.
    View in: PubMed
    Score: 0.005
  36. Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res. 2005 Oct; 2(4):419-23.
    View in: PubMed
    Score: 0.004
  37. Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res. 2004 Mar 01; 75(5):698-703.
    View in: PubMed
    Score: 0.004
  38. Oxidative damage to nucleic acids in human prion disease. Neurobiol Dis. 2002 Apr; 9(3):275-81.
    View in: PubMed
    Score: 0.003
  39. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis. 2002 Mar; 9(2):244-8.
    View in: PubMed
    Score: 0.003
  40. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett. 2002 Feb 08; 319(1):25-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.